Late recurrence is a risk for some pediatric cancers, particularly Ewing sarcomas and tumors of the central nervous system, according to a new study published online December 4 in the Journal of the National Cancer Institute.
This study was undertaken because there is limited research on late recurrence (after 5 years and up to 20 years) for pediatric cancer patients.
Karen Wasilewski-Masker, M.D., of the Aflac Cancer Center and Blood Disorders Service, Children's Healthcare of Atlanta at Scottish Rite, and colleagues analyzed data from the Childhood Cancer Survivor Study for 12,795 five-year survivors of the most common pediatric cancers. Cumulative incidence of late recurrence at 5, 10, 15, and 20 years after diagnosis was calculated using death as a competing risk.
The overall pediatric cancer recurrence rate was 4.4% at 10 years and 6.2% at 20 years among 5-year survivors. Thirteen percent of Ewing sarcomas and 14.4% of astrocytomas had recurred by 20 years. Only 0.9% of pediatric kidney tumors, 2.4% of Non-Hodgkin lymphomas, and 2.6% of neuroblastomas had recurred in 5 year-survivors by 20 years after treatment.
"Future research is needed to determine the risk of recurrence in subgroups of survivors and the cost-effectiveness of long-term disease surveillance in at-risk patient groups because these factors need to be considered in long-term follow-up and transitional care plans," the authors write.
Contacts:
Emory University: Ashante Dobbs, ADOBBS2@emory.edu, 404-727-5692
The Aflac Cancer Center at Children's Healthcare of Atlanta: Brant Rawls, Brant.Rawls@choa.org, 404.785.7577
Note to Reporters:
The Journal of the National Cancer Institute is published by Oxford University Press and is not affiliated with the National Cancer Institute. Attribution to the Journal of the National Cancer Institute is requested in all news coverage.
Visit JNCI online at http://jnci.oxfordjournals.org and the JNCI press room at http://www.oxfordjournals.org/our_journals/jnci/press_room.html
For the latest cancer news and studies, follow us on Twitter @JNCI_Now
Journal
JNCI Journal of the National Cancer Institute